Plain-English translation of NCT06352242 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is looking at CAR-T cell therapy, a personalized cancer treatment that trains your own immune cells to fight lymphoma. The research team wants to understand whether measuring a specific immune process called trogocytosis in your blood shortly after treatment can predict whether the medication will work well for you and whether you might experience serious side effects.
CAR-T cell therapy helps some patients with aggressive lymphoma live longer, but it doesn't work for everyone—and doctors currently have no way to predict who will respond or who might have dangerous complications. This study aims to find an early warning sign using blood tests, so doctors can better understand how your immune system is responding to the treatment.
You likely qualify if…
You likely don't qualify if…
As a participant, you will have blood samples drawn at specific time points—starting at the time of your CAR-T cell infusion and continuing through the first month after treatment. Your blood will be analyzed to measure immune cell activity. The study team will also follow up with you at six months to see how well your treatment worked. Healthy volunteers will provide a single blood sample for comparison.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
France